Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT-I7 in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy
NCT07200089Phase 1Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Jun 2026
- Primary completion
- Mar 2028
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of efineptakin alfa in multiple myeloma (MM) (5 arms), sponsored by Washington University School of Medicine. Primary endpoints: Rate of non-hematologic grade >=3 treatment-related adverse events and Recommended phase II dose. Started Jun 2026; status: recruiting.
02
Drugs
efineptakin alfa
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07200089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07200089.